Ir J Med Sci (2017) 186:615–620 DOI 10.1007/s11845-017-1582-3 ORIGINAL ARTICLE Evaluating cardioversion outcomes for atrial ﬁbrillation on novel oral anticoagulants versus warfarin: experience at a tertiary referral centre 1 1 1 1 1 1 • • • • • • Z. Sharif B. Srinivas I. Tiedt N. Ryan M. Awadalla V. Sullivan 1 1 1 1,2 • • • D. P. Foley T. Gumbrielle B. McAdam R. G. Sheahan Received: 4 August 2016 / Accepted: 17 February 2017 / Published online: 24 February 2017 Royal Academy of Medicine in Ireland 2017 Abstract elective DCCV and additional anticoagulant monitoring Background Current guidelines recommend anticoagula- was estimated at €1160 per procedure. tion prior to cardioversion in patients with atrial ﬁbrillation Conclusion In elective cardioversions, the group antico- of [48 h or unknown duration to reduce thromboembolic agulated with NOAC was less likely to have subtherapeutic risk. Therapeutic anticoagulation with warfarin, with INR anticoagulation and hence deferred procedures and had between 2 and 3, is consistently achieved in approximately reduced health care consumption when compared to the 60% of patients. group anticoagulated with warfarin. Aims We evaluated outcomes and assessed differences in direct current cardioversion (DCCV) in patients treated Keywords Atrial ﬁbrillation
Irish Journal of Medical Science (1971 -) – Springer Journals
Published: Feb 24, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera